More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 27, 2024 -- In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep. 26 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Hilda Razzaghi, Ph.D., from the CDC in Atlanta, and colleagues conducted an internet survey panel during March 26 to April 11, 2024, to examine maternal and infant RSV immunization coverage for the 2023 to 2024 RSV season.
The researchers found that 32.6 percent of 678 women at 32 to 36 weeks of gestation during September 2023 to January 2024 reported receipt of an RSV vaccine during pregnancy. Overall, 44.6 percent of 866 women with an infant born during August 2023 to March 2024 reported infant receipt of nirsevimab. More than half (55.8 percent) of infants were protected by maternal RSV vaccine, nirsevimab, or both. There was an association seen for provider recommendation for maternal vaccination or infant nirsevimab with higher immunization coverage; the main reason for not getting RSV immunization was lack of a provider recommendation. Concern about long-term safety for the infant was the main reason for definitely or probably not getting nirsevimab for infants.
"Recommendations from health care providers are critical to improving RSV immunization coverage for both pregnant women and their infants and reducing severe RSV disease among infants," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Ziresovir Reduces Signs, Symptoms of Bronchiolitis in Babies With RSV
FRIDAY, Sept. 27, 2024 -- For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis...
RSV Vaccination Effective Against Hospitalization in Patients 60 Years and Older
THURSDAY, Sept. 5, 2024 -- For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 -- Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.